Company Overview of Neurotech Pharmaceuticals, Inc.
Neurotech Pharmaceuticals, Inc., a biotechnology company, develops transformative therapies for chronic eye diseases. Its products are based on encapsulated cell therapy (ECT), which is a genetically engineered ocular implant that enables continuous production of therapeutic proteins to the eye for a period of two years. The company offers NT-503 ECT, which is intended for use in the treatment of neo-vascular age-related macular degeneration; NT-506 ECT, which delivers anti-platelet-derived and anti-vascular endothelial growth factor proteins in a single implant; and NT-501 ECT, which is intended for use in treatment of retinal degenerative diseases. Neurotech Pharmaceuticals, Inc. was forme...
900 Highland Corporate Drive
Cumberland, RI 02864
Founded in 1995
Key Executives for Neurotech Pharmaceuticals, Inc.
Chief Financial Officer, Chief Operating Officer and Director
Vice President of Core Technology Development
Vice President of Manufacturing
Compensation as of Fiscal Year 2017.
Neurotech Pharmaceuticals, Inc. Key Developments
Neurotech Pharmaceuticals, Inc. Announces Positive Phase 2 Results in NT-501 (CNTF) for Macular Telangiectasia
Jun 20 17
Neurotech Pharmaceuticals, Inc., in collaboration with the Lowy Medical Research Institute (LMRI), announced 24-month results demonstrating that NT-501 delivering Ciliary Neurotrophic Factor (CNTF) has a beneficial effect in patients with Macular Telangiectasia type 2 (MacTel). The multicenter, randomized clinical trial demonstrated a statistically significant reduction in the progressive loss of photoreceptors in treated versus untreated eyes. NT-501 utilizes the Company's proprietary Encapsulated Cell Therapy (ECT) platform that can be customized to deliver specific therapeutic molecules to the back of the eye for retinal disease. The Phase 2 study enrolled 67 patients (99 eyes) at eight sites in the United States and three in Australia. Eligible eyes were randomized to receive either the NT-501 implant containing CNTF or a sham procedure. The primary endpoint, change in the ellipsoid zone from baseline to month 24, was measured by Spectral Domain Optical Coherence Tomography (SD-OCT). An increase in the area of the ellipsoid zone is a measure of disease progression in patients with MacTel and is correlated with loss of photoreceptors leading to visual loss. At 24 months, there was significantly less photoreceptor loss in eyes treated with NT-501 versus sham. The area of ellipsoid zone break increased by 0.213 mm2 in sham eyes compared to 0.148 mm2 in treated eyes. The difference in the increase of the MacTel lesion (0.065 mm2) was statistically significant (p=0.030). The proportion of study eyes with a 35% or more increase from baseline in the ellipsoid zone was significantly reduced in the treated group (p = 0.045) and macular thickness was significantly increased in the treated population when compared to the control group (p=0.007). Secondary clinical outcomes showed reading speed being maintained in the study eyes while deteriorating in the sham eyes (p=0.016). NT-501 was generally well tolerated, consistent with previous studies of NT-501 in retinitis pigmentosa and dry AMD. No participants had the implant removed during the course of the study. The majority of adverse events were related to the surgical procedure. In all cases these surgery-related events were resolved within 3 months.
Neurotech Presents at Leerink Healthcare Summit, Sep-22-2016 11:30 AM
Sep 19 16
Neurotech Presents at Leerink Healthcare Summit, Sep-22-2016 11:30 AM. Venue: Napa Valley, California, United States. Speakers: James V. Mazzo, Global President of Ophthalmic Medical Devices, ZEISS & Chairman.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking
Most Searched Private Companies
Sponsored Financial Commentaries